JP
PCRX icon

John Paulson’s Pacira BioSciences PCRX Stock Holding History

John Paulson’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-350,000
Closed -$20.4M – 30
2022
Q2 		$20.4M Sell
350,000
-150,000
-30% -$9.83M 1.01% 19
2022
Q1 		$38.2M Sell
500,000
-1,205,599
-71% -$80.4M 1.17% 21
2021
Q4 		$103M Buy
1,705,599
+446,081
+35% +$24.6M 3.16% 8
2021
Q3 		$70.5M Sell
1,259,518
-13,643
-1% -$786K 2.01% 12
2021
Q2 		$77.3M Sell
1,273,161
-140,693
-10% -$8.91M 1.85% 16
2021
Q1 		$99.1M Hold
1,413,854
– – 2.28% 12
2020
Q4 		$84.6M Buy
1,413,854
+158,246
+13% +$9.27M 2.2% 13
2020
Q3 		$75.5M Sell
1,255,608
-34,333
-3% -$1.99M 2.35% 12
2020
Q2 		$67.7M Sell
1,289,941
-426,786
-25% -$17.8M 2.16% 13
2020
Q1 		$57.6M Hold
1,716,727
– – 2.2% 14
2019
Q4 		$77.8M Hold
1,716,727
– – 1.68% 14
2019
Q3 		$65.4M Buy
1,716,727
+757,730
+79% +$30.2M 1.31% 20
2019
Q2 		$41.7M Buy
958,997
+708,997
+284% +$30.1M 0.71% 28
2019
Q1 		$9.52M Buy
+250,000
New +$9.76M 0.2% 39

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

John Paulson's PCRX Position: Q3 2022 in Review

John Paulson sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 350,000 shares — an estimated $20.4M sold.

John Paulson first reported a position in PCRX in Q1 2019 and held it in 14 quarters. The position peaked at $103M in Q4 2021. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

  • John Paulson reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
  • John Paulson sold 350,000 Pacira BioSciences shares in Q3 2022, an estimated $20.4M.
  • John Paulson first reported a position in Pacira BioSciences in Q1 2019 and held it in 14 quarters.
  • John Paulson's Pacira BioSciences position peaked at $103M in Q4 2021.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Paulson & Co's 13F filing for Q3 2022, filed 14 Nov 2022.